Effects of orally administered actinidia arguta (hardy kiwi) fruit extract on 2-chloro-1,3,5-trinitrobenzene-induced atopic dermatitis-like skin lesions in nc/nga mice

Journal of Medicinal Food

Volumn 12, Issue 5, 2009, Pages 1004-1015

  Kim, Ji Yun ^a   Lee, In Ki ^b   Son, Mi Won ^b   Kim, Kyu Han ^a  

^a Seoul National University Hospital   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

Actinidia arguta; Atopic dermatitis; Immunomodulation

Indexed keywords

ACTINIDIA ARGUTA EXTRACT; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 4; PICRYL CHLORIDE; PLANT EXTRACT; TACROLIMUS; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ACTINIDIA ARGUTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EPIDERMIS; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; MALE; MAST CELL; MAST CELL DEGRANULATION; MEDICINAL PLANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SKIN CELL; SKIN DEFECT; SPLEEN CELL;

ACTINIDIA; ADMINISTRATION, ORAL; ANIMALS; DERMATITIS, ATOPIC; DEXAMETHASONE; EPIDERMIS; FRUIT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; MAST CELLS; MICE; MODELS, ANIMAL; PHYTOTHERAPY; PLANT EXTRACTS; SEVERITY OF ILLNESS INDEX; SKIN; TACROLIMUS; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 9; TRINITROBENZENES; UP-REGULATION;

ACTINIDIA ARGUTA; ANIMALIA; MUS;

EID: 70350506797     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2009.0080     Document Type: Article

References (38)

1. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA: New insights into atopic dermatitis. J Clin Invest 2004;113:651-657.
2. Morar N, Willis-Owen SA, Moffatt MF, Cookson WO: The genetics of atopic dermatitis. J Allergy Clin Immunol 2006;118: 24-34; quiz 35-36.
3. Akdis CA, Akdis M, Trautmann A, Blaser K: Immune regulation in atopic dermatitis. Curr Opin Immunol 2000;12:641-646.
4. Vickery BP: Skin barrier function in atopic dermatitis. Curr Opin Pediatr 2007;19:89-93.
5. Lubbe J: Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003;4:641-654.
6. Ring J, Kramer U, Schafer T, Behrendt H: Why are allergies increasing? Curr Opin Immunol 2001;13:701-708.
7. Leung DY, Jain N, Leo HL: New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol 2003;15:634-638.
8. Wollenberg A, Bieber T: Atopic dermatitis: from the genes to skin lesions. Allergy 2000;55:205-213.
9. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
10. Baker BS: The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006;144:1-9.
11. Leung DY, Bieber T: Atopic dermatitis. Lancet 2003;361:151-160.
12. Kotani M, Matsumoto M, Fujita A, et al.: Persimmon leaf extract and astragalin inhibit development of dermatitis and IgE elevation in NC=Nga mice. J Allergy Clin Immunol 2000;106:159-166.
13. Oku H, Ishiguro K: Antipruritic and antidermatitic effect of extract and compounds of Impatiens balsamina L. in atopic dermatitis model NC mice. Phytother Res 2001;15:506-510.
14. Ziment I, Tashkin DP: Alternative medicine for allergy and asthma. J Allergy Clin Immunol 2000;106:603-614.
15. Chen L, Lucas JS, Hourihane JO, et al.: Evaluation of IgE binding to proteins of hardy (Actinidia arguta), gold (Actinidia chinensis) and green (Actinidia deliciosa) kiwifruits and processed hardy kiwifruit concentrate, using sera of individuals with food allergies to green kiwifruit. Food Chem Toxicol 2006;44: 1100-1107.
16. Park EJ, Park KC, Eo H, et al.: Suppression of spontaneous dermatitis in NC=Nga murine model by PG102 isolated from Actinidia arguta. J Invest Dermatol 2007;127:1154-1160.
17. Park EJ, Kim B, Eo H, et al.: Control of IgE and selective TH1 and TH2 cytokines by PG102 isolated from Actinidia arguta. J Allergy Clin Immunol 2005;116:1151-1157.
18. Vestergaard C, Yoneyama H, Matsushima K: The NC=Nga mouse: a model for atopic dermatitis. Mol Med Today 2000;6: 209-210.
19. Suto H, Matsuda H, Mitsuishi K, et al.: NC=Nga mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol 1999; 120(Suppl 1):70-75.
20. Bio-Rad: Bio-Rad Technical Note 2861. Principles of Curve Fitting for Multiplex Sandwich Immunoassays. http:==www .bio-rad.com (accessed July 13, 2009).
21. Miraglia del Giudice M, Decimo F, Leonardi S, et al.: Immune dysregulation in atopic dermatitis. Allergy Asthma Proc 2006;27: 451-455.
22. Hamid Q, Boguniewicz M, Leung DY: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;94:870-876.
23. Leung DY: Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860-876.
24. Fiset PO, Leung DY, Hamid Q: Immunopathology of atopic dermatitis. J Allergy Clin Immunol 2006;118:287-290.
25. Ou LS, Goleva E, Hall C, Leung DY: T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004;113:756-763.
26. Cookson W: The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004;4:978-988.
27. Strachan DP: Family size, infection and atopy: the first decade of the "hygiene hypothesis." Thorax 2000;55(Suppl 1):S2-S10.
28. Maintz L, Novak N: Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol 2007;17:267-283.
29. Horner AA, Redecke V, Raz E: Toll-like receptor ligands: hygiene, atopy and therapeutic implications. Curr Opin Allergy Clin Immunol 2004;4:555-561.
30. Fiset PO, Tulic MK, Hamid Q: Toll-like receptors and atopy. J Allergy Clin Immunol 2005;116:467-470.
31. Mrabet-Dahbi S, Dalpke AH, Niebuhr M, et al.: The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis. J Allergy Clin Immunol 2008;121:1013-1019.
32. Eder W, Klimecki W, Yu L, et al.: Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 2004;113:482-488.
33. Arbour NC, Lorenz E, Schutte BC, et al.: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-191.
34. Inoue J, Aramaki Y: Suppression of skin lesions by transdermal application of CpG-oligodeoxynucleotides in NC=Nga mice, a model of human atopic dermatitis. J Immunol 2007;178:584-591.
35. Inoue J, Yotsumoto S, Sakamoto T, Tsuchiya S, Aramaki Y: Changes in immune responses to mite antigen sensitized through barrier-disrupted skin with CpG-oligodeoxynucleotide in mice. Biol Pharm Bull 2006;29:385-387.
36. Takakura M, Takeshita F, Aihara M, et al.: Hyperproduction of IFN-gamma by CpG oligodeoxynucleotide-induced exacerbation of atopic dermatitis-like skin lesion in some NC=Nga mice. J Invest Dermatol 2005;125:1156-1162.
37. Schnare M, Barton GM, Holt AC, et al.: Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001;2:947-950.
38. Li ZW, Rickert RC,KarinM: Genetic dissection of antigen receptor induced-NF-kappaB activation. Mol Immunol 2004;41:701-714.